Key Highlights
- Cadrenal Therapeutics received a reiterated Buy rating and $13 price target from H.C. Wainwright.
- The rating follows a Type D meeting where the FDA aligned on the CAD-1005 Phase 3 primary endpoint and trial design.
- The trial targets heparin-induced thrombocytopenia (HIT).
- Initiation of the study is contingent upon securing additional funding or a strategic partnership.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) received a reiterated Buy rating and $13 price target from H.C. Wainwright following a Type D meeting where the FDA aligned on the CAD-1005 Phase 3 primary endpoint and placebo-controlled trial design for heparin-induced thrombocytopenia.
What Happened
The regulatory agreement provides a clear registrational pathway, though the initiation of the study is currently contingent upon securing additional funding or a strategic partnership.
Market Reaction
The disclosed information does not include stock price or trading data for Cadrenal Therapeutics following the reiterated rating.
Outlook
Securing additional funding or a strategic Partnership represents the key near-term step before Cadrenal Therapeutics can initiate its Phase 3 trial for CAD-1005 in HIT.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.